Loading...
Please wait, while we are loading the content...
Similar Documents
HSF1 is involved in immunotherapeutic response through regulating APOJ/STAT3-mediated PD-L1 expression in hepatocellular carcinoma.
| Content Provider | Europe PMC |
|---|---|
| Author | Cheng, Hongxia Wang, Sikai Huang, Aidan Ma, Jing Gao, Dongmei Li, Miaomiao Chen, Huaping Guo, Kun |
| Copyright Year | 2022 |
| Abstract | ABSTRACTHepatocellular cancer (HCC) is a serious illness with high prevalence and mortality throughout the whole world. For advanced HCC, immunotherapy is somewhat impactful and encouraging. Nevertheless, a substantial proportion of patients with advanced HCC are still unable to achieve a durable response, owing to heterogeneity from clonal variability and differential expression of the PD-1/PD-L1 axis. Recently, heat shock factor 1 (HSF1) is recognized as an important component of tumor immunotherapeutic response as well as related to PD-L1 expression in cancer. However, the mechanism of HSF1 regulating PD-L1 in cancer, especially in HCC, is still not fully clear. In this study, we observed the significantly positive correlation between HSF1 expression and PD-L1 expression in HCC samples; meanwhile combination expressions of HSF1 and PD-L1 served as the signature for predicting prognosis of patients with HCC. Mechanistically, HSF1 upregulated PD-L1 expression by inducing APOJ expression and activating STAT3 signaling pathway in HCC. In addition, we explored further the potential values of targeting the HSF1-APOJ-STAT3 axis against CD8+ T cells-mediated cancer cells cytotoxicity. These findings unveiled the important involvement of HSF1 in regulating PD-L1 expression in HCC as well as provided a novel invention component for improving the clinical response rate and efficacy of PD-1/PD-L1 blockade. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9746510&blobtype=pdf |
| Page Count | 9 |
| ISSN | 15384047 |
| Journal | Cancer Biology & Therapy [Cancer Biol Ther] |
| Volume Number | 24 |
| DOI | 10.1080/15384047.2022.2156242 |
| PubMed Central reference number | PMC9746510 |
| Issue Number | 1 |
| PubMed reference number | 36482717 |
| e-ISSN | 15558576 |
| Language | English |
| Publisher | Taylor & Francis |
| Publisher Date | 2023-12-01 |
| Access Restriction | Open |
| Rights License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. |
| Subject Keyword | Hepatocellular carcinoma immunotherapy HSF1 PD-L1 APOJ JAK/STAT3 |
| Content Type | Text |
| Resource Type | Article |
| Subject | Cancer Research Molecular Medicine Pharmacology Oncology |
